UK digital obesity service with tirzepatide achieves 22.6% weight loss in adherent patients at 12 months | Research

The takeaway

Among 19,693 UK patients in a tirzepatide-supported digital weight loss service, the 27% who adhered for 12 months achieved 22.6% weight loss, with consistent weekly engagement (not intensive daily tracking) being the strongest predictor of success.

22.6% weight loss at 12 months
The 27% of patients who adhered to the digital tirzepatide program achieved near-clinical-trial weight loss, with moderate weekly engagement the key predictor of success

What the researchers found

19,693 patients. 12-month adherence: 27% (5,322). Adherent weight loss: 22.6% ± 7.46%. Full cohort (LOCF): 13.6% ± 10.85%. Best predictor: consistent weekly engagement (tracking, coaching). Intensive daily tracking and rapid early loss predicted dropout.

Why it matters

At 22.6%, this is among the highest real-world weight loss results ever reported, demonstrating that tirzepatide + comprehensive digital support can approach clinical trial efficacy. The adherence insight—moderate pacing beats intensive tracking—is directly actionable.

How the study worked

Retrospective cohort of 19,693 Juniper UK DWLS patients on tirzepatide. LOCF for full cohort. Logistic regression (adherence predictors) and linear regression (weight loss predictors).

What this study cannot tell us

Retrospective. 27% adherence means 73% dropped out. Self-selected population. No control group. Digital literacy may bias participation.

How to read the evidence

Large retrospective cohort (19,693). High attrition limits generalizability. Strong predictive modeling.

When this study was published

Published in 2025.

The bigger picture

This is the largest real-world tirzepatide weight loss study. The finding that moderate behavioral pacing outperforms intensive tracking could reshape digital health intervention design for obesity.

Questions still open

How can the 73% dropout rate be improved?
Would less intensive engagement targets improve adherence?
Is the 22.6% loss maintained beyond 12 months?

Common questions

How much weight can you lose on tirzepatide in real life?

In this UK program of 19,693 patients, those who stuck with treatment for 12 months lost an average of 22.6% of their body weight—close to clinical trial results. Even counting those who dropped out, the average was 13.6%. The key was consistent weekly engagement with the digital support program.

What predicts success with tirzepatide?

Surprisingly, moderate weekly engagement (checking in, attending coaching sessions) was the strongest predictor—not intensive daily tracking or rapid early weight loss. Patients who tried to do too much too quickly were more likely to drop out. Sustainable, moderate pacing produced the best 12-month results.

Read the original research

12-Month Weight Loss and Adherence Predictors in a Real-World UK Tirzepatide-Supported Digital Obesity Service: A Retrospective Cohort Analysis.

Healthcare (Basel, Switzerland), 14(1)

View on PubMed ↗Publisher’s paper ↗

Citation

Talay, Louis; Hom, Jason; Scott, Tamara; Ahuja, Neera. (2025). 12-Month Weight Loss and Adherence Predictors in a Real-World UK Tirzepatide-Supported Digital Obesity Service: A Retrospective Cohort Analysis.. Healthcare (Basel, Switzerland), 14(1). https://doi.org/10.3390/healthcare14010060